Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III booster trial of WSK-V102C trivalent recombinant COVID-19 protein vaccine
ChiCTR2300073044Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Coviccine Trivalent XBB, recombinant COVID-19 variant vaccine and saline in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Efficacy against first symptomatic PCR-confirmed COVID-19 after day 14 and Incidence of adverse events and adverse reactions through day 7. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
Coviccine Trivalent XBBrecombinant COVID-19 variant vaccinesaline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300073044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073044.